Drug Profile
Naproxen/esomeprazole SR - Hanmi
Alternative Names: HCP 1004Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors; Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in South Korea (PO)
- 12 Dec 2012 Phase-I clinical trials in Rheumatoid arthritis in South Korea (PO)